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maltophiliaassociated (HCA) infection in the community-onset group and to compare them with hospital-
acquired (HA) SMBSI patients.
Materials and methods: Medical charts of adult patients with SMBSI presenting to a medical
center in southern Taiwan from May 2008 to October 2011 were reviewed and analyzed retro-
spectively.
Results: Among 153 patients, we observed a high percentage (38.6%) of SMBSI to be community
onset. Among community-onset SMBSI, 45.8% were community-acquired (CA) and 54.2% were
HCA. The crude mortality rates were 11.1%, 18.8%, and 60.6% in the CA, HCA, and HA groups,
respectively. Structural/mechanical abnormalities were observed in 32.7% of all cases, and
60% of those were related to malignancy. Independent risk factors for mortality in
community-onset SMBSI were liver cirrhosis, liver metastasis, and a high Pitt bacteremia score,
whereas structural/mechanical abnormalities and a high Pitt bacteremia score related to
increased mortality in HA SMBSI.
Conclusion: Community-onset S. maltophilia infection deserves attention. Patients with
community-onset SMBSI have reduced disease severity and lower mortality rate when compared
to HA SMBSI. Underlying structural/mechanical abnormalities, especially those caused bymalig-
nancies, are common in SMBSI cases and should be investigated when bacteremia occurs.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Stenotrophomonas maltophilia, formerly named Pseudo-
monas and then Xanthomonas maltophilia, is a ubiquitous
aerobic nonfermentative Gram-negative bacillus that exists in
humid environments, water sources, soil, and plants.1
Because of its limited pathogenicity and multidrug resis-
tance, S. maltophilia is considered to be an opportunistic
pathogenandan importantnosocomial pathogen.Reports of it
causing community-acquired (CA) infection are uncommon.2
Risk factors for S. maltophilia infection include underlying
malignancy, presence of indwelling devices, chronic respira-
tory diseases, immunocompromised status, prior use of anti-
biotics, and long-term stay in the hospital or intensive care
unit (ICU).1 Characteristics of community-onset S.maltophilia
infection and its importance have not been clearly described.
One recent review article focusing on CA S. maltophilia
infections concluded that S. maltophilia infections are not
restricted to hospitalized patients.2 Case reports and series
gave a glimpse into the various manifestations of S. malto-
philia infections in community settings, including meningitis,
endocarditis, wound and soft-tissue infection, bacteremia,
sinusitis, osteochondritis, chronic enteritis, and other condi-
tions.2 However, to our knowledge, no study has offered
a comprehensive perspective on community-onset S. malto-
philia infections. This retrospective study aimed to elucidate
the patient demographics and clinical features of community-
onset S. maltophilia bloodstream infection (SMBSI). In addi-
tion, we used clear definitions of CA, healthcare-associated
(HCA), and hospital-acquired (HA) infections, and compared
the differences and risk factors for mortality between these
specific patient groups.
Materials and methods
Settings and study design
This retrospective study was conducted in a 1700-bed
tertiary hospital in southern Taiwan from May 2008 toOctober 2011. The study population enrolled adult
patients, aged 18 years, with S. maltophilia bacteremia.
Medical charts were reviewed and all data were recorded
under the approval of the hospital’s Institutional Review
Board. Only the clinical characteristics of the first episode
of bacteremia were analyzed for each patient.Definitions
Bloodstream infection is defined as the isolation of bacteria
from one or more peripheral venous blood samples
collected from a patient associated with the symptoms and
signs relevant to systemic infection. The probable source
(including respiratory, urinary, gastrointestinal, skin and
soft tissue, bone, and joint) was determined by microbio-
logical results and physicians’ clinical interpretations
according to Centers for Disease Control (CDC) definitions.3
Catheter-related bloodstream infections were defined
according to the management guidelines of the Infectious
Diseases Society of America, if there was no apparent
source for the bacteremia except the central venous
catheter (CVC) and when the organism was isolated in
a positive semiquantitative culture (>15 CFU) from the CVC
tip with a positive peripheral blood culture for the same
organism.4 Hospital-acquired bloodstream infection (HABSI)
was defined by a positive blood culture obtained from
patients who were hospitalized for >48 hours. Community-
onset bloodstream infection (COBSI) was defined by a posi-
tive blood culture obtained from patients who were either
not hospitalized or hospitalized for 48 hours.
The community-onset group was further divided into HCA
and CA subgroups. The relationship among the three
subgroups is presented in Fig. 1. COBSI was defined by
a positive blood culture drawn within 48 hours after hospi-
talization for patients who did not attend any healthcare
facilities in 90 days or reside in nursing home.5e7 Episodes
were considered HCA according to the definition of Fried-
man et al,5 if the patient fulfilled any of the following
criteria: (1) received intravenous therapy at home, received
Figure 1. Relationship among patient subgroups.
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intravenous medical therapy in the 30 days before the
bloodstream infection; (2) attended a hospital or hemodi-
alysis clinic or received intravenous chemotherapy within 30
days before the bloodstream infection; (3) was hospitalized
in an acute care hospital for 2 or more days within 90 days
before the bloodstream infection; or (4) resided in a nursing
home or long-term care facility. Polymicrobial bacteremia
was defined as the presence of one or more microorganism
other than S. maltophilia in the same blood culture. A
previous chemotherapy, surgery, or invasive procedure
(including percutaneous transhepatic gallbladder drainage,
percutaneous abscess drainage, and percutaneous neph-
rostomy) was recorded only when performed within 3
months of the SMBSI. Steroid therapy was defined as the use
of more than 30 mg daily or an equivalent dose of prednis-
olone for more than 7 days before the bloodstream infec-
tion. Neutropenia was defined as an absolute neutrophil
count of<500/mm3 at the onset of bacteremia. Appropriate
antimicrobial treatment refers to the administration of an
adequate dose of an in vitro susceptible antibiotic within 72
hours after the blood culture was obtained and for more
than 7 days. Structural or mechanical abnormality was
recorded when there was documented imaging or endo-
scopic evidence of gastrointestinal, hepatopancreatobiliary,
and urinary tract anomalies including liver metastases,
pancreatobiliary tract or urinary system dilatation/
obstruction,8,9 fistulas, mechanical ileus, or severe muco-
sitis/enteritis caused by chemotherapy, infection, or
inflammatory bowel disease.10
Microbiology
Blood cultures were incubated with BacT/Alert system
(Organon Teknika, Massachusetts, USA). Species and anti-
microbial susceptibility were determined using VITEK-2
(bioMerieux, Inc., Saint Louis County, Missouri, USA).
Susceptibility testing results were interpreted according to
the Clinical and Laboratory Standards Institute guidelines,
2010.11
Statistical analysis
All data were analyzed using the Statistical Package for
Social Sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL,USA). Values were expressed as the mean standard devi-
ation (continuous variables) or percentages of the group
(categorical variables). Continuous variables were
compared using Student t test. Categorical variables were
evaluated with the chi-squared test or Fisher’s exact test,
as appropriate. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated. Two-tailed tests were used
and p< 0.05 was considered significant. Variables with
p< 0.1 in univariate testing were incorporated into
a forward, stepwise multivariate logistic regression model
to identify independent predictors for mortality.Results
From May 2008 to October 2011, 167 episodes of S. malto-
philia bacteremia were identified in 153 patients after the
exclusion of five patients under the age of 18 years. The
study population was divided into three groups: CA, HCA,
and HA. These three groups comprised 17.6% (nZ 27), 21%
(nZ 32), and 61.4% (nZ 94) of the patients, respectively.
Demographic and clinical characteristics of the patients are
shown in Table 1. There were no differences in age, sex,
and body mass index among the three groups. Both the HCA
and the HA groups had higher percentages of underlying
malignant disease than the CA group (59.4% vs. 14.8%,
p< 0.001; 41.5% vs. 14.8%, pZ 0.003 respectively).
Among patients with malignancy (nZ 62), 10 had
hematologic malignancy, 52 had solid tumors, and one had
both. The three most common solid tumors were gastro-
intestinal tumors (nZ 23, 44.2%), followed by head and
neck tumors (nZ 10, 19.2%) and hepatopancreatobiliary
tumors (nZ 9, 17.3%). There were five patients with newly
diagnosed or suspected malignancy at the time of bacter-
emia. Among them, four had hepatopancreatobiliary
tumors and one had urothelial carcinoma, all causing
obstructive biliary tract infection or obstructive nephrop-
athy. We observed more liver metastases in cancer
patients with community-onset S. maltophilia bacteremia
(CA group: 25%, HCA group: 36.8%) when compared with
the HA group (15.4%). The HCA group had similar clinical
conditions to those of the HA group regarding previous
chemotherapy, surgery, and invasive procedures. Most of
the surgeries performed were gastrointestinal (44%) and
cardiovascular (32%). There were significantly longer
length of ICU stay, higher crude mortality and 14-day
mortality, and more episodes of polymicrobial bacter-
emia in the HA group. Candidemia constituted the highest
percentage of polymicrobial episodes (19.2%), followed by
coagulase-negative staphylococci (15.4%) and methicillin-
resistant Staphylococcus aureus (15.4%). The average
number of hospitalized days before SMBSI was 35.1. The
HCA group had the highest Charlson Comorbidity Index, but
the HA group had the highest Pitt bacteremia score (PBS).
The HCA and HA groups had higher prevalence rates of
catheter-related bloodstream infection (18.8% and 20.2%)
and infections of unknown source (31.1% and 55.3%).
We found that the most frequent infection sources in the
CA group were respiratory tract infection (12/27, 44.4%),
followed by gastrointestinal (5/27, 18.5%) and urinary tract
infection (4/27, 14.8%). Among the five patients with
a gastrointestinal source of infection, two patients had
Table 1 Comparison of demographic and clinical characteristics of patients suffering from community-onset and hospital-
acquired S. maltophilia bacteremia (nZ 153)
Parameters CO (nZ 59) p
CA (nZ 27) HCA (nZ 32) HA (nZ 94)
n (%) n (%) n (%) CA vs. HCA HCA vs. HA CA vs. HA
Age 57.9 (20.4) 66.0 (14.2) 65.2 (16.0) 0.079 0.795 0.053
75 7 (25.9) 9 (28.1) 34 (36.2) 0.850 0.407 0.322
Sex
Male 12 (44.4) 18 (56.3) 50 (53.2) 0.366 0.764 0.423
Body weight 57.5 (13.8) 55.5 (11.6) 58.6 (13.4) 0.582 0.258 0.724
BMI 22.6 (4.4) 22.2 (4.1) 22.6 (4.5) 0.703 0.681 0.946
Underlying diseases
Malignancy 4 (14.8) 19 (59.4) 39 (41.5) <0.001 0.080 0.003
Hematologic 0 (0.0) 2 (6.3) 8 (8.5) 0.495 1.000 0.197
Solid tumor 4 (14.8) 17 (53.1) 31 (33) 0.003 0.043 0.091
Hypertension 10 (37.0) 13 (40.6) 47 (50.0) 0.778 0.359 0.234
Diabetes mellitus 6 (22.2) 15 (46.9) 31 (33.0) 0.049 0.158 0.285
COPD 2 (7.4) 4 (12.5) 8 (8.5) 0.678 0.499 1.000
Chronic heart failure 3 (11.1) 6 (18.8) 10 (10.6) 0.488 0.234 1.000
Chronic renal failure 3 (11.1) 9 (28.1) 25 (26.6) 0.193 0.866 0.122
Liver cirrhosis 2 (7.4) 4 (12.5) 15 (16.0) 0.678 0.779 0.356
Liver metastasesa 1 (25) 7 (36.8) 6 (15.4) 1.000 0.013 0.421
CCI 1.89 (2.2) 5.68 (2.7) 3.89 (2.9) <0.001 0.003 0.001
Clinical conditions
Corticosteroid use 0 (0.0) 0 (0.0) 13 (14.0) 0.038 0.039
Chemotherapy 0 (0.0) 7 (23.3) 16 (17.0) 0.011 0.539 0.021
Appropriate antibiotics 8 (29.6) 13 (40.6) 63 (67.0) 0.380 0.008 0.001
Neutropenia 0 (0.0) 3 (9.4) 5 (5.3) 0.243 0.418 0.586
Tracheostomy 0 (0.0) 3 (9.4) 14 (14.9) 0.243 0.557 0.038
S/M abnormalities 6 (22.2) 13 (40.6) 31 (33) 0.132 0.433 0.285
Surgeryb 0 (0.0) 13 (40.6) 37 (39.4) <0.001 0.900 <0.001
GS 0 (0.0) 6 (46.2) 16 (43.2) 0.024 0.710 0.012
CVS 0 (0.0) 4 (30.8) 12 (32.4) 0.112 1.000 0.067
Polymicrobial 1 (3.7) 1 (3.1) 21 (22.3) 1.000 0.014 0.025
Crude mortality 3 (11.1) 6 (18.8) 57 (60.6) 0.488 <0.001 <0.001
14-d mortality 2 (7.4) 4 (12.5) 36 (38.3) 0.678 0.008 0.002
LOS 9.0 (12.1) 15.3 (12.5) 60.2 (72.9) 0.056 0.001 <0.001
ICU LOS 1.52 (7.1) 2.25 (6.8) 19.7 (20.2) 0.688 <0.001 <0.001
PBS 0.41 (1.2) 1.97 (3.6) 4.1 (3.8) 0.027 0.007 <0.001
Source of bacteremia
Respiratory 12 (44.4) 4 (12.5) 14 (14.9) 0.008 1.000 0.001
Urinary 4 (14.8) 4 (12.5) 1 (1.1) 1.000 0.015 0.009
Gastrointestinal 5 (18.5) 5 (15.6) 7 (7.4) 0.768 0.173 0.09
Skin and soft tissue 1 (3.7) 3 (9.4) 1 (1.1) 0.617 0.050 0.398
Osteomyelitis 1 (3.7) 0 (0) 0 (0) 0.458 0.225
Catheter related 0 (0.0) 6 (18.8) 19 (20.2) 0.027 0.858 0.007
Pelvic inflammatory disease 1 (3.7) 0 (0) 0 (0) 0.458
Unknown source 3 (11.1) 10 (31.1) 52 (55.3) 0.113 0.019 <0.001
a Percentage among cancer patients.
b Including invasive procedures as previously defined in the text. The GS and CVS percentages refer to the ratio within the patients who
underwent surgery or invasive procedures.
BMIZ body mass index; CAZ community acquired; CCIZ Charlson Comorbidity Index; COZ community onset; COPDZ chronic
obstructive pulmonary disease; CVCZ central venous catheter; CVSZ cardiovascular surgery; GSZ gastrointestinal surgery;
HAZ hospital acquired; HCAZ healthcare associated; IADZ intra-abdominal drainage; ICUZ intensive care unit; LOSZ length of
stay; PBSZ Pitt bacteremia score; S/M abnormalitiesZ structural/mechanical abnormalities.
Community-onset S. maltophilia bloodstream infection 31
Figure 3. Yearly susceptibility to TMP/SMX overall and
among the three groups. CAZ community acquired;
HCAZ healthcare associated; HAZ hospital acquired; TMP/
SMXZ trimethoprim/sulfamethoxazole.
32 Y.-T. Chang et al.biliary tract infection with biliary tract dilatation due to
suspected periampullary space-occupying lesions and newly
diagnosed pancreatic tumors, respectively. The other three
patients had pancreatitis, adhesion ileus, and enteritis.
Less common infection sources in the CA group included
cellulitis (one patient), osteomyelitis (one patient), pelvic
inflammatory disease (one patient), and no definite infec-
tion source (four patients).
In vitro antimicrobial susceptibilities of S. maltophilia to
trimethoprim/sulfamethoxazole (TMP/SMX), levofloxacin,
and minocycline were 68.9% (115/167), 89.8% (150/167),
and 99.4% (166/167), respectively. Fig. 2 shows the anti-
microbial susceptibilities in the three subgroups of CA,
HCA, and HA SMBSI. They all had high susceptibility to
minocycline and levofloxacin, and the CA group had the
lowest susceptibility to TMP/SMX. We analyzed the annual
antimicrobial susceptibility rate and found significantly
increasing TMP/SMX susceptibility during the study period
in the CA (pZ 0.046) and HCA (pZ 0.013) groups.
Increasing susceptibility was not observed with levofloxacin
or minocycline. The annual TMP/SMX susceptibility rate is
depicted in Fig. 3.
Because the HCA group showed a lower mortality rate
similar to the CA group, we performed the analysis of
mortality risk factors in the two subgroups of COBSI and
HABSI. Univariate analysis identified several risk factors for
mortality in both COBSI and HABSI (Table 2). In the multi-
variate analysis (Table 2), liver cirrhosis, liver metastases,
and high PBS were identified as independent risk factors for
mortality in the COBSI group, whereas structural/mechan-
ical abnormalities and high PBS were shown to be signifi-
cant in the HABSI group.
Discussion
S. maltophilia has been recognized as an important
opportunistic nosocomial pathogen. However, its impor-
tance in community-onset infection is seldom stressed. This
study is, to our knowledge, the first retrospective study in
the English-language literature to compare the demo-
graphic characteristics, clinical parameters, and mortality
risk factors between community-onset and HA SMBSI and to
emphasize the specific group of HCA SMBSI.Figure 2. Antimicrobial susceptibilities in the three subgroups.
CAZ community acquired; HCAZ healthcare associated;
HAZ hospital acquired; LEVZ levofloxacin; MNOZminocy-
cline; TMP/SMXZ trimethoprim/sulfamethoxazole.We observed a relatively high percentage (38.6%) of
SMBSI to be community onset when compared to the 8e24%
mentioned in previous studies.2,12e18 Falagas et al2
proposed, as a limitation in their review, that the defini-
tion of CA infection lacked clarity. When we used clear
definitions to document CA and HCA infections,5 we found
that community-onset infections were increasing and CA
infections were underestimated.
Similar to a recently published study on SMBSI by Garazi
et al,17 the present study also enrolled a broad spectrum of
patient population and represents the largest series of
SMBSI, whereas most of the previous studies involved either
a much smaller number of cases or patients with
a predominant enrollment from cancer hospitals.17 Garazi
et al divided the infections into nosocomial (77.5%, nZ 79),
HCA (20.6%, nZ 21), and CA (2.0%, nZ 2) without any
comparison between the three groups. Although their
definition of HCA infection was not exactly identical to our
study, we observed a similar HCA ratio and a much higher
percentage of CA SMBSI.
Previous studies seldom described CA S. maltophilia
infections in detail, and there was significant heterogeneity
in patient populations. Falagas et al2 concluded that the
majority of patients with CA S. maltophilia infections had
some kind of comorbidity, and it was difficult to infer about
the outcomes in these infections.2 In our observation, we
found that there was no significant difference regarding
underlying comorbidities when compared to the other two
groups, except for lower prevalence of malignancy.
Mortality rate was lowest among the three groups, even
though only 29.6% of the patients were prescribed appro-
priate antibiotics.
Despite hematologic malignancy (34e57%) and neu-
tropenia (23e53%), both being reported as common coex-
isting conditions in SMBSI,13,15,19 we found an exceptionally
low prevalence of hematologic malignancy and neutropenia
in the present study. On the contrary, one-third of the
patients had solid tumors, similar to the findings of previous
reports (9e37%).
We also noted that 32.7% of our patients had docu-
mented structural/mechanical abnormalities (Table 1), 60%
of which were directly related to malignancy. We hypoth-
esize that the bacteremia could be a result of bacterial
Table 2 Univariate and multivariate analyses of risk factors associated with mortality in patients with S. maltophilia
bacteremia
Risk factor Community onset (nZ 59) Hospital acquired (nZ 94)
OR (95% CI) Adjusted OR (95% CI) OR (95% CI) Adjusted OR (95% CI)
Patient profiles
Age 0.483 (0.97e1.06) 1.031 (0.99e1.04)
Male 10.182 (1.18e87.63) 0.548 (0.24e1.27)
Medical conditions
Cancer 1.422 (0.34e5.98) 0.888 (0.38e2.05)
Liver cirrhosis 7.833 (1.28e47.96) 14.923 (0.99e222.92)a 0.969 (0.31e2.99)
Liver metastases 4.5 (0.851e23.80) 23.098 (1.89e281.86)a 0.630 (0.12e3.30)
CCI 1.418 (1.08e1.86) 1.069 (0.922e1.24)
S/M abnormalities 1.867 (0.44e7.94) 3.117 (1.17e8.28) 4.064 (1.41e11.69)a
Polymicrobial 6.125 (0.35e108.11) 1.395 (0.50e3.87)
Unknown infection source 6.562 (1.44e29.91) 2.713 (1.16e6.36)
Interventions
Chemotherapy NA 0.318 (0.10e0.97)
Appropriate antibiotics 0.466 (0.09e2.48) 1.174 (0.49e2.82)
Severity score
PBS 1.47 (1.12e1.94) 1.784 (1.15e2.78)a 1.247 (1.08e1.44) 1.279 (1.11e1.48)a
a Significant in multivariate analysis.
NAZ not available; ORZ odds ratio; CIZ confidence interval; CCIZ Charlson Comorbidity Index; PBSZ Pitt bacteremia score.
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mucosal disruption and barrier defects caused by tumor
invasion. Although colonization of S. maltophilia and its
relationship to infection were not clearly demonstrated,
our observation is in accord with the findings from previous
reports in which structural anomalies were identified, in
most of the cases, with biliary and urinary tract S. malto-
philia infection.9,14,20e23 Besides, structural/mechanical
abnormalities correlated to increased mortality in the HA
group. We believe that investigating possibly obstructive
lesions and performing drainage or debridement may be of
value in respect of treatment.
Previous literature has reported a wide range in crude
mortality (21e69%) associated with SMBSI.19,24 An attrib-
utable mortality of 26e37.5% has been reported.25,26 In this
study, we found that the crude mortality rates in the
community-onset group were significantly lower than in the
HA group. We also found the HCA group to be a unique
category to have milder disease conditions and better
outcomes than the HA group, despite having higher
comorbidity scores. Thrombocytopenia, shock,13 neu-
tropenia, polymicrobial bacteremia with enterococci,19 ICU
stay, CVC use, and mechanical ventilation12 were all re-
ported as risk factors associated with mortality in S. mal-
tophilia bacteremia. Multivariate analysis indicated liver
cirrhosis and liver metastases to be independent risk
factors for mortality in the COBSI group but not in the HABSI
group. This finding implies that the underlying hep-
atobiliary comorbidities may be of more predictive value
for mortality in COBSI than in HABSI. There is still contro-
versy about whether administration of inappropriate anti-
biotics relates to increased mortality in current reports,17
and we found no correlations between appropriate antibi-
otics use and mortality.S. maltophilia is renowned for its intrinsic resistance to
various antimicrobial agents, and TMP/SMX is considered to
be the drug of choice.27 However, resistance rates to TMP/
SMX are highly variable in different regions, with a general
susceptibility over 80%, except for high resistance reported
in Taiwan (25%), Spain (27%), and Turkey (15%).27,28 In
recent studies conducted at various medical centers in
Taiwan examining S. maltophilia infections and antimicro-
bial susceptibility, susceptibility to TMP/SMX ranges from
14.3% to 91%.12,13,29e34 Most of the study populations had
nosocomial infections. Only two studies mentioned an
increasing resistance trend against TMP/SMX, which
differed from our observation.13,32 We observed a statisti-
cally significant increasing susceptibility to TMP/SMX in
isolates from the community-onset group during
2008e2011, but not in the HA group (Fig. 3). The mecha-
nism is not clear from the current data. The high suscep-
tibility to minocycline during our study period is similar to
the observations of a 10-year multicenter retrospective
study in Taiwan; however, we did not see increasing resis-
tance to levofloxacin.34
The retrospective nature of this study is its major limi-
tation. We also had a polymicrobial bacteremia rate of
22.3% in the HABSI group, which makes it difficult to assess
the influence of SMBSI on mortality. The number of patients
who died in the CABSI group was too small for analysis. Risk
factors for mortality among the CA, HCA, and HA SMBSI
groups could be analyzed separately to better distinguish
between the three groups when more cases are available.
This study is the first attempt to describe the differences
between CA, HCA, and HA SMBSI groups. We suggest that
S. maltophilia not only causes HA infections but also
emerges as a pathogen in community settings. Although
community-onset SMBSI was represented with lower
34 Y.-T. Chang et al.mortality, the observation should be emphasized due to the
limited antimicrobial options for S. maltophilia. Liver
cirrhosis and liver metastases were found as predictors of
a higher mortality among S. maltophilia COBSI patients.
Underlying structural/mechanical abnormalities should be
investigated when S. maltophilia bacteremia is confirmed,
especially in patients with malignancy.Conflicts of interest
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